Merck & Company (MRK) Receives ‘Analyst’ Rating

Merck & Company (MRK) : 6 brokerage houses believe that Merck & Company (MRK) is a Strong Buy at current levels. 7 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Merck & Company (MRK). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 13 Wall Street Analysts endorse the stock as a Buy with a rating of 2.08.

Merck & Company (MRK) : The most positive equity analysts on Merck & Company (MRK) expects the shares to touch $80, whereas, the least positive believes that the stock will trade at $56 in the short term. The company is covered by 12 Wall Street Brokerage Firms. The average price target for shares are $65.92 with an expected fluctuation of $7.65 from the mean.


Also, Barclays maintains its rating on Merck & Company (NYSE:MRK). The global brokerage major raises the current price target from $66 per share to $72 per share. Analysts at the Barclays have a current rating of Overweight on the shares. The rating by the firm was issued on September 9, 2016.

Merck & Company (NYSE:MRK): After opening at $61.24, the stock dipped to an intraday low of $61.12 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $62.605 and the buying power remained strong till the end. The stock closed at $62.38 for the day, a gain of 1.68% for the day session. The total traded volume was 9,026,862. The stocks close on the previous trading day was $61.35.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.